High response rate to darbopoetin alfa in "low risk" MDS: Results of a phase II study.

被引：0
|
作者：
Mannone, L [1 ]
Gardin, C [1 ]
Quarre, MC [1 ]
Bernard, JF [1 ]
Giraudier, S [1 ]
Rosenthal, E [1 ]
Vassilief, D [1 ]
Hamza, F [1 ]
Park, S [1 ]
Kiladjian, JJ [1 ]
Vaultier, S [1 ]
Beyne-Rouzy, M [1 ]
Cheze, S [1 ]
Voilliat, L [1 ]
Agape, P [1 ]
Dreyfus, F [1 ]
Fenaux, P [1 ]
机构：
[1] GFM, Paris 13, France
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
69
引用
收藏
页码：24A / 24A
页数：1
相关论文
共 50 条
  • [1] High response rate to Epoetin Beta in elderly patients with myelodysplasia (MDS): Results of a prospective study.
    Chaibi, P
    Gouin, I
    Berigaud, S
    Siguret, V
    Pautas, E
    Schlageter, MH
    Rain, JD
    Raffoux, E
    BLOOD, 2005, 106 (11) : 713A - 713A
  • [2] ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study
    Hanamoto, Hitoshi
    Morita, Yasuyoshi
    Ichikawa, Motoshi
    Nannya, Yasuhito
    Shibayama, Hirohiko
    Maeda, Yoshinobu
    Hata, Tomoko
    Miyamoto, Toshihiro
    Kawabata, Hiroshi
    Takeuchi, Kazuto
    Tanaka, Hiroko
    Kishimoto, Junji
    Miyano, Satoru
    Matsumura, Itaru
    Ogawa, Seishi
    Akashi, Koichi
    Kanakura, Yuzuru
    Mitani, Kinuko
    BLOOD, 2020, 136
  • [3] High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR)+/-G-CSF in Lower-Risk MDS: a Phase II Study
    Kelaidi, Charikleia
    Beyne-Rauzy, Odile
    Braun, Thorsten
    Cougou, Pierre
    Ades, Lionel
    Pillard, Fabien
    Lamberto, Christine
    Jernival, Tony
    Mortera, Edith
    Guerci, Agnes
    Choufi, B.
    Stamatoullas, Aspasia
    Slama, Borhane
    De Renzis, Benoit
    Ame, S.
    Ghandi, Damaj
    Boyer, Francoise
    Chaury, Marie-Pierre
    Legros, Laurence
    Cheze, Stephane
    Testu, Anna
    Gyan, Emmanuel
    Bene, Marie C.
    Rose, Christian
    Dreyfus, Francois
    Fenaux, Pierre
    BLOOD, 2009, 114 (22) : 1467 - 1467
  • [4] Arsenic trioxide in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase II clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Ellison, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 561S - 561S
  • [5] Trisenox® (Arsenic trioxide) in patients (pts) with myelodysplastic syndromes (MDS):: Preliminary results of a phase II study.
    Vey, N
    Blaise, D
    Damaj, G
    Gastaut, JA
    Garzon, F
    Paradise, C
    Panning, L
    BLOOD, 2002, 100 (11) : 342B - 342B
  • [6] Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):: Preliminary results of a phase I/II study.
    Vey, N
    Dreyfus, F
    Guerci, A
    Fenaux, P
    Dombret, H
    Burnett, AK
    Bosly, A
    Feremans, W
    Bowen, DT
    Heiskala, M
    BLOOD, 2004, 104 (11) : 401A - 402A
  • [7] Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
    Modak, Shakeel
    Kushner, Brian H.
    Mauguen, Audrey
    Castaneda, Alicia
    Varo, Amalia
    Gorostegui, Maite
    Munoz, Juan Pablo
    Santa-Maria, Vicente
    Basu, Ellen M.
    Cardenas, Fiorella Iglesias
    Pandit-Taskar, Neeta
    Cheung, Nai-Kong V.
    Mora, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients.
    Wijermans, P
    Lübbert, M
    Verhoef, G
    Bosly, A
    Ravoet, C
    Andre, M
    Ferrant, A
    BLOOD, 1998, 92 (10) : 632A - 632A
  • [9] Effectiveness of darbepoetin alfa vs epoetin alfa in patients with anemia resulting from myelodysplastic syndrome (MDS): results of a retrospective cohort study.
    Patten, JE
    Sullivan, T
    Mun, Y
    Wallace, J
    PHARMACOTHERAPY, 2005, 25 (03): : 468 - 468
  • [10] High response rate to Epoetin Beta in elderly patients with myelodysplasia (MDS): Results of a prospective study
    Chaibi, P.
    Gouin, I.
    Berigaud, S.
    Siguret, V.
    Pautas, E.
    Schlageter, M. H.
    Raffoux, E.
    Piette, F.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S26 - S26
12345